Buccal insulin may be back in India after Phase III results
This article was originally published in Scrip
Shreya Life Sciences, the Indian licensee of Generex Biotechnology Corporation, has submitted details of its recently completed Phase III trial of Generex Oral-lyn, the Canadian firm's buccal insulin spray product, to the Indian government seeking approval for marketing and commercialisation.
You may also be interested in...
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.